1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
A series of case studies illustrating the role of flow cytometry in the diagnostic work-up of myelodysplastic syndromes
(
- Contribution to journal › Article
-
Mark
Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow working group
(
- Contribution to journal › Article
-
Mark
Multiparameter flow cytometry in the evaluation of myelodysplasia : Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group
(
- Contribution to journal › Scientific review
-
Mark
Flow cytometric analysis of myelodysplasia : Pre-analytical and technical issues—Recommendations from the European LeukemiaNet
(
- Contribution to journal › Article
-
Mark
Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome : A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group
(
- Contribution to journal › Article
- 2022
-
Mark
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia : Results from the HEAT-AML trial
(
- Contribution to journal › Article
- 2020
-
Mark
Enumeration of CD34+ blasts by immunohistochemistry in bone marrow biopsies from MDS patients may have significant impact on final WHO classification
(
- Contribution to journal › Article
- 2015
-
Mark
Detection of central nervous system involvement in childhood acute lymphoblastic leukemia by cytomorphology and flow cytometry of the cerebrospinal fluid
(
- Contribution to journal › Article
- 2014
-
Mark
p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)
(
- Contribution to journal › Article
- 2011
-
Mark
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
(
- Contribution to journal › Article